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ABSTRACT 
TITLE : Comparative study of neoadjuvant chemotherapy in hormone receptor 
positive and negative locally advanced breast carcinoma 
BACKGROUND  AND  AIMS 
            Locally advanced breast carcinoma is a diverse and heterogeneous group 
of breast cancer common in developing countries. Though, thought initially as 
incurable , is now being cured by the use of neoadjuvant chemotherapy and 
surgery. The study aimed in evaluating the clinical and pathological response of 
locally advanced breast carcinoma to neoadjuvant chemotherapy with respect to 
its hormone receptor status and also the feasibility of surgery in inoperable 
locally advanced breast carcinoma. 
SETTING & DESIGN 
        A prospective comparative study conducted in General Surgery department 
in Tirunelveli Medical College from January 2016 to March 2017. 
MATERIALS AND METHODS 
       50  locally advanced breast carcinoma patients were selected as study 
subjects and divided into two groups, based on their hormone receptor status as 
hormone receptor positive (ER+,PR+)  and  hormone receptor negative.(ER-
,PR-). All these patients were given 3 cycles of neoadjuvant chemotherapy- 
FAC regimen: Cyclophosphamide – 500 mg/m2, 5-Fluorouracil- 500 mg/m2, 
Adriamycin- 50 mg/m2 , followed which the response to chemotherapy was 
measured . The patients who were operable after neoadjuvant chemotherapy 
were subjected to surgery (Modified radical mastectomy) and the mastectomy 
specimens were sent for histo-pathological analysis and the pathological 
response was studied. 
Patients with neoplasms of breast other than locally advanced breast carcinoma, 
tumours with Her-2 neu receptor positivity, inflammatory carcinoma of breast 
were excluded from the study. 
STATISTICAL ANALYSIS 
All continuous variables were analysed using student’s t test and 
categorical variables by chi -square test. 
RESULTS 
Mean age of the study population was 47 years and mean tumour size 
was 8 cms. 50 patients were enrolled, out of which 37 patients (74%) were 
hormone receptor positive and 13 patients (26%) were hormone receptor 
negative. Complete clinical response was observed in 13 patients(26%), partial 
response in 32 patients (64%) and stable disease in 5 patients (10%). Out of 
these, 18.9% of complete clinical response occurred in hormone receptor  
positive patients whereas it was  46.1% in hormone receptor negative patients. 
Partial clinical response being 70.2% and 46.1% in hormone receptor positive 
and negative patients respectively. Overall the response rate was good in 
hormone receptor negative patients  ( 92.3%).  All the hormone receptor 
negative patients were operable after 3 cycles of chemotherapy. All the 7 
patients who were inoperable were hormone receptor positive.  
    Similarly, complete pathological response was seen in 9 patients (21%), 
partial response in 25 patients (58%) and residual disease in 9 patients (21%). 
38.4% of hormone receptor negative patients achieved complete pathological 
response on comparing with hormone receptor positive group (13.3%). Partial 
pathological response and residual disease in hormone negative patients were 
46.1% and 15.3% respectively. Pathological response rate was also higher in 
hormone receptor negative patients (84.6%). 
CONCLUSION 
Neoadjuvant chemotherapy helps in downstaging of locally advanced 
breast carcinoma and renders inoperable tumours operable. Response to 
chemotherapy varies with hormone receptor status. Clinical and pathological 
response to chemotherapy is higher in hormone receptor negative patients. 
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